ADVERTISEMENT

Real-world data show semaglutide benefit in type 2 diabetes

Miriam Tucker E.   |   Clinical Summary   |   01 March 2023
ADVERTISEMENT

Takeaway

  • Real-world data demonstrate clinically significant glucose-lowering with the once-weekly subcutaneous human glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide in adults with type 2 diabetes for up to 720 days in both GLP-1RA experienced and naive people.
  • Approximately 1 of 4 patients discontinued treatment during the first 6 months.

Why this...

          

November Challenge

Ends in 1d 15h
left
right

Topic Challenges

left
right